Neuronal or inducible nitric oxide synthase (NOS) expression level is not involved in the different susceptibility to nigro-striatal dopaminergic neurotoxicity induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) between C57BL/6 and BALB/c mice

Experimental and Toxicologic Pathology

Volumn 65, Issue 1-2, 2013, Pages 121-125

  Ito, Tsuyoshi ^a   Uchida, Kazuyuki ^a   Nakayama, Hiroyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

BALB c mice; C57BL 6 mice; INOS; MPP+; MPTP; NNOS; Strain difference

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; DOPAMINE; DOPAMINE TRANSPORTER; INDUCIBLE NITRIC OXIDE SYNTHASE; MONOCLONAL ANTIBODY; NEURONAL NITRIC OXIDE SYNTHASE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE PREDISPOSITION; DISEASE RESISTANCE; DOPAMINERGIC SYSTEM; IMMUNOHISTOCHEMISTRY; MALE; MESENCEPHALON; MOUSE; NERVE CELL; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PROTEIN EXPRESSION; STRAIN DIFFERENCE; SUBSTANTIA NIGRA PARS COMPACTA; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CORPUS STRIATUM; DISEASE SUSCEPTIBILITY; DOPAMINERGIC NEURONS; ENZYME INDUCTION; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MPTP POISONING; NITRIC OXIDE SYNTHASE TYPE II; SPECIES SPECIFICITY; SUBSTANTIA NIGRA;

MUS;

EID: 84870247046     PISSN: 09402993     EISSN: 16181433     Source Type: Journal    
DOI: 10.1016/j.etp.2011.06.009     Document Type: Article

References (23)

1. Brooks W.J., Jarvis M.F., Wagner G.C. Astrocytes as a primary locus for the conversion MPTP into MPP+. J Neural Transm 1989, 76:1-12.
2. Chalimoniuk M., Lukacova N., Marsala J., Langfort J. Alterations of the expression and activity of midbrain nitric oxide synthase and soluble guanylyl cyclase in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. Neuroscience 2006, 141:1033-1046.
3. Comini L., Bachetti T., Gaia G., Pasini E., Agnoletti L., Pepi P., et al. Aorta and skeletal muscle NO synthase expression in experimental heart failure. J Mol Cell Cardiol 1996, 28:2241-2248.
4. Dehmer T., Lindenau J., Haid S., Dichgans J., Schulz J.B. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 2000, 74:2213-2216.
5. Filipov N.M., Norwood A.B., Sistrunk S.C. Strain-specific sensitivity to MPTP of C57BL/6 and BALB/c mice is age dependent. Neuroreport 2009, 20:713-717.
6. Franklin K.B.J., Paxinos G. The mouse brain in stereotaxic coordinates 2007, Academic Press, London.
7. Hamre K., Tharp R., Poon K., Xiong X., Smeyne R.J. Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus. Brain Res 1999, 828:91-103.
8. Joniec I., Ciesielska A., Kurkowska-Jastrzebska I., Przybylkowski A., Czlonkowska A., Czlonkowski A. Age- and sex-differences in the nitric oxide synthase expression and dopamine concentration in the murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res 2009, 1261:7-19.
9. Kitayama S., Wang J.B., Uhl G.R. Dopamine transporter mutants selectively enhance MPP+ transport. Synapse 1993, 15:58-62.
10. Klivenyi P., Andreassen O.A., Ferrante R.J., Lancelot E., Reif D., Beal M.F. Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity. Neuroreport 2000, 11:1265-1268.
11. Le Couteur D.G., Leighton P.W., McCann S.J., Pond S. Association of a polymorphism in the dopamine-transporter gene with Parkinson's disease. Mov Disord 1997, 12:760-763.
12. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999, 5:1403-1409.
13. Liu J., Wang M.W., Gu P., Ma Q.Y., Wang Y.Y., Geng Y., et al. Microglial activation and age-related dopaminergic neurodegeneration in MPTP-treated SAMP8 mice. Brain Res 2010, 1345:213-220.
14. Muramatsu Y., Kurosaki R., Watanabe H., Michimata M., Matsubara M., Imai Y., et al. Cerebral alterations in a MPTP-mouse model of Parkinson's disease-an immunocytochemical study. J Neural Transm 2003, 110:1129-1144.
15. Muthane U., Ramsay K.A., Jiang H., Jackson-Lewis V., Donaldson D., Fernando S., et al. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice. Exp Neurol 1994, 126:195-204.
16. Obata T., Yamanaka Y. Nitric oxide enhances MPP(+)-induced hydroxyl radical generation via depolarization activated nitric oxide synthase in rat striatum. Brain Res 2001, 902:223-228.
17. Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V.L., Dawson T.M. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA 1996, 93:4565-4571.
18. Ransom B.R., Kunis D.M., Irwin I., Langston J.W. Astrocytes convert the Parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+. Neurosci Lett 1987, 75:323-328.
19. Sedelis M., Hofele K., Auburger G.W., Morgan S., Huston J.P., Schwarting R.K. MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 2000, 30:171-182.
20. Smeyne R.J., Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain Res Mol Brain Res 2005, 134:57-66.
21. Sundström E., Strömberg I., Tsutsumi T., Olson L., Jonsson G. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res 1987, 405:26-38.
22. Yasuda Y., Shimoda T., Uno K., Tateishi N., Furuya S., Yagi K., et al. The effects of MPTP on the activation of microglia/astrocytes and cytokine/chemokine levels in different mice strains. J Neuroimmunol 2008, 204:43-51.
23. Zimmer J., Geneser F.A. Difference in monoamine oxidase B activity between C57 black and albino NMRI mouse strains may explain differential effects of the neurotoxin MPTP. Neurosci Lett 1987, 78:253-258.